Skip to main content

Table 5 Sensitivity analyses, age standardised disability-adjusted life years (DALYs) per 100,000 population, and percentage difference (%Diff) as compared to the main analysis, Norway 2008

From: Estimating and validating disability-adjusted life years at the global level: a methodological framework for cancer

Cancer sites

Sensitivity analysis 1a

Sensitivity analysis 2b

DALYs

%Diff

DALYs

%Diff

Lip oral cavity

46

2

46

2

Nasopharynx

3

0

3

0

Other pharynx

33

3

33

3

Oesophagus

80

1

80

1

Stomach

152

0

152

−1

Colorectum

643

1

643

0

Liver

48

0

48

0

Gallbladder

34

0

34

0

Pancreas

248

0

248

0

Larynx

20

5

- c

- c

Lung

864

1

864

0

Melanoma of skin

180

1

180

0

Kaposi Sarcoma

-d

-d

-d

-d

Breast

587

4

587

3

Cervix uteri

102

1

102

1

Corpus uteri

84

1

84

0

Ovary

151

1

- e

- e

Prostate

364

9

364

4

Testis

44

0

- e

- e

Kidney

110

2

108

0

Bladder

105

1

105

1

Brain, nervous system

281

3

- c

- c

Thyroid

11

0

- e

- e

Hematological cancers

- f

- f

- f

- f

  1. a Sensitivity analysis 1: Two-stage disease model as compared to three stage disease model.
  2. b Sensitivity analysis 2: Proportion of advanced cases used as proxy of patients who did not receive (curatively intentioned) treatment as compared to use of available treatment data.
  3. c Staging data were not available.
  4. d Treatment and staging data were not available.
  5. e Proportion cured was larger than proportion of advanced cases, analysis was not done.
  6. f Sensitivity analyses 1 and 2 were not done for haematological cancers.